The molecular and electrophysiological mechanism of buyanghuanwu decoction in learning and memory ability of vascular dementia rats.
Buyanghuanwu Decoction (BYHWD), as a traditional Chinese medicine, has been developed to treat vascular dementia for hundreds of years, but the underlying mechanisms remain unknown. In this research, the protective effects of BYHWD on hippocampal neuron were examined in the rats of ischemia-reperfusion. Ischemia-reperfusion injury was induced by the four-vessel occlusion method and continued for 30 days. BYHWD (per 6.25g/kg/d) was orally given to rats twice each day for 30 days after ischemia-reperfusion, Nimodipine (per 10mg/kg/d) was orally given to rats twice each day for 30 days. In VD+BYHWD group rats, the neuronal injury in the hippocampal CA1 region was significantly less than that of VD group's. BYHWD of intragastric administration also markedly increased the expression of Extracellular signal-regulated kinase 2 (ERK2) and Calcium/calmodulin-dependent protein kinaseII (CaMKIIIy)in the CA1 region. Our results suggested that increased ERK2 and CaMKIIIy due to BYHWD may partially account for its effect of neuroprotection standing against ischemic injury in the hippocampal CA1 region, and participated in the rebuilding of synapse, strengthened the expression of LTP, promoted the ability recover of learning and memory in VD rats.
Department of Pathophysiology, Chengde Medical College, Chengde, Hebei 067000, China.
Tang
T
Jinglong
Gao
G
Weijuan
Li
L
Jun
Qian
Q
Tao
Zhang
Z
Hongbo
Liu
L
Shasha
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004558:Electric Stimulation; D005786:Gene Expression Regulation / Q000187:drug effects; D006624:Hippocampus / Q000473:pathology; D020287:In Situ Nick-End Labeling; D017774:Long-Term Potentiation / Q000187:drug effects; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000187:drug effects; D009553:Nimodipine / Q000627:therapeutic use; D051381:Rats; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D002121:Calcium Channel Blockers; D004365:Drugs, Chinese Herbal; C460102:buyang huanwu; D009553:Nimodipine; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; C517676:Camk2b protein, rat; D019950:Mitogen-Activated Protein Kinase 1
Buyanghuanwu Decoction; ERK2 and CaMKIIIy; Hippocampus CA1 region; LTP; Learning and memory; Rats